Moreover, our data indicate that further characterization of PBRM1 bromodomain missense variants in the context of cancer pathogenesis and therapeutic response is mechanistically and clinically warranted to improve precision medicine approaches for cancer treatment. The gene discussed is PBRM1; the disease is cancer.